Breakthrough Minimally Invasive Surgery Transforms Pancreatic Tumor Treatment

Laparoscopic duodenum-preserving pancreatic head resection in 459 patients for precancerous, cystic neoplasms, and neuroendocrine tumors. Perioperative outcome: systematic review and meta-analysis.

Surgical endoscopy • • Review • Moderately Relevant
🤖

AI Summary

This research paper focuses on a specialized surgical technique for treating pancreatic tumors, specifically examining laparoscopic duodenum-preserving pancreatic head resection (L-DPPHRt). The study analyzed 459 patients with various pancreatic neoplasms, including intraductal papillary mucinous neoplasms (IPMNs), mucinous cystic neoplasms (MCNs), and pancreatic neuroendocrine tumors (PNETs).

The researchers discovered that this minimally invasive surgical approach offers significant benefits for patients. The procedure demonstrated extremely low mortality rates of just 0.43%, with minimal complications. Operative time was significantly shorter (239 minutes compared to 343 minutes for alternative procedures), and blood loss was substantially reduced (128 ml versus 240 ml). The technique proved particularly effective for treating benign and premalignant pancreatic tumors, with a very low risk of serious postoperative complications.

Key surgical outcomes included low rates of pancreatic fistula (18.08%), minimal biliary fistula (7.62%), and extremely low rates of reoperation (2.47%). The procedure was especially promising for patients with cystic neoplasms and pancreatic neuroendocrine tumors larger than 2 cm, offering a potentially curative approach with minimal surgical risk.

📄 Original Abstract

With regard to laparoscopic approach, the objective arises whether standard multiorgan Whipple resection (PD) or parenchyma-sparing procedures (DPPHRt) are the most qualified surgical treatments for benign, premalignant neoplasms. Pubmed, Embase, Medline, and Cochrane Libraries were searched for studies reporting results and late outcomes after laparoscopic DPPHRt (L-DPPHRt) and laparoscopic PD (L-PD) for benign tumors. Data of 19 cohort studies including 459 patients were assessed. Results of six controlled trials comprising 129 L-DPPHRt and 205 L-PD for benign neoplasms were compared. L-DPPHRt was performed for 123 IPMNs, 44 MCNs, 98 SPNs, 102 SCNs, and 59 PNETs. 90-day mortality was 2 of 459 patients (0.43%). Pancreatic fistula B/C occurred in 83 patients (18.08%) and biliary fistula in 35 patients (7.62%). Incidence of POPF B + C following complete and incomplete L-DPPHRt was 36/256 pats. (14.06%) and 40/167 pats. (23.95%) (p = 0.030), respectively. LHS was 14.24 days (mean). Laparoscopic total DPPHR unveiled very low risk of hospital mortality (1/459 pats.;0.21%), reoperation (9/364 pats.;2.47%), DGE (14/280 pats.;5.0%), CBD stenosis (2/459 pats.;0.43%), and ischemic lesion of CBD (2/459 pats.;0.43%). Comparing 129 L-DPPHRt with 205 L-PD patients revealed overall mean values of 239. vs. 343 min. for OP time and 128 ml vs. 240 ml for estimated blood loss. Meta analysis using standardized mean difference (SMD) demonstrated these differences to be significant (OP time: SMD - 1.20, 95% CI - 2.08 to 0.31; p = 0.008; blood loss: SMD - 1.77, 95% CI - 2.87 to - 0.66; p = 0.002). L-DPPHRt was associated with better intraoperative and early postoperative performance. Laparoscopic DPPHR for cystic neoplasms and PNETs is a low-risk procedure leading to cure of patients. L-DPPHRt accomplishes the most appropriate goals for treatment of patients with benign, premalignant, cystic neoplasms, and PNETs (> 2 cm) of the pancreatic head.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.